Targazyme, Inc. , a clinical-stage biopharmaceutical company developing novel enzyme technologies and products to improve efficacy outcomes for cancer immunotherapy and cell therapy, announced today the receipt of an SBIR award to fund the development of genetically-modified mesenchymal stem cells treated with Targazyme's lead product, TZ101 for ... (more)
http://ift.tt/1nzPrNx
http://ift.tt/1nzPrNx
No comments:
Post a Comment